Advertisement

Topics

Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference

08:00 EDT 23 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present data from Part A and Part B of the MoveDMD trial of edasalonexent (CAT-1004) in an oral prese...

Other Sources for this Article

Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com

NEXT ARTICLE

More From BioPortfolio on "Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...